Approved for U.S. Patent and Talemark Office U.S. Patent and Talemark Office Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10727318			
Filing Date		2003-12-03			
First Named Inventor Hens		bergen			
Art Unit		2116			
Examiner Name	Suge	ent, James			
Attorney Docket Number		AU920030763US1			

Examiner C Initial* N	Cite No	Patent Number	Kind			B
1			Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5148546		1992-09-15	Blodgett	
2	2	5404543		1995-04-04	Faucher, et al.	
3	3	6330639	B1	2001-12-11	Fanning, et al.	
4	4	6657634		2003-12-02	Sinclair, et al.	
6	5	6704877	B2	2004-03-09	Cline, et al.	
6	6	6834353	B2	2006-06-09	Smith, et al.	
7	7	7000130	B2	2006-02-14	Adachi	
If you wish t	to ad	ld additional U.S. Pat	ent citatio	n information p	lease click the Add button.	Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10727318	
iling Date		2003-12-03	
irst Named Inventor Hens		bergen	
Art Unit		2116	
Examiner Name Suge		nt, James	
Attorney Docket Number		AU920030763US1	

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant iment	Releva		Lines where ges or Relev	
	1	20030210247	A1	2003-1	1-13	Cui, et al.					
	2	20020004913	A1	2006-0	5-09	Fung					
	3	20040236896	A1	2004-1	1-25	Kanapathippill	lai, et al.				
	4	20040260957	A1	2004-1	2-23	Jeddeloh, et a	ı.				
If you wis	h to a	dd additional U.S. Publi:						d button	$\overline{}$		_
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴ Publication Code ⁴ Name of Patentee or Applicant of cited Document Passages or Relevant Passages or		evant or Relevant	TA			
	1										
If you wisl	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*						Тs					
	1										
If you wis	h to ac	dd additional non-paten	t literatu	re docu	ment cit	ation informati	ion please click the	Add bu	utton Ad	ld	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10727318	
	Filing Date		2003-12-03	
	First Named Inventor Hens		bergen	
	Art Unit		2116	
	Examiner Name	Suge	nt, James	
	Attorney Docket Numb	er	AU920030763US1	

EXAMINER SIGNATURE							
Examiner Signature		Date Considered					
	reference considered, whether or not citation is in conformation and not considered. Include copy of this form with						

1 See Kin Codes of USPTO Patent Documents at year LISPTO,GOV or MPEP 901.6. Firster office that issued to document, by the ho-letter code (WIPO Standard ST3.3 For Juapense plateful accounted), the validation of the year of the Proprior mater procedule the serial number of the plateful accounted. If Anni of document by the appropriate symbols as exclusived on the document under WIPO Standard ST.16 if possible. 3 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10727318	
Filing Date			2003-12-03	
First Named Inventor Henst		Hens	bergen	
Art Unit			2116	
		Suge	nt, James	
		er	AU920030763US1	

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mitch Harris#42,638/	Date (YYYY-MM-DD)	2006-06-08
Name/Drint	Andrew Mitchell Hopic	Desistration Number	42020

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 3T CFR. 11.4 This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.